Trinity Biotech plc (ADR) (NASDAQ:TRIB) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: September 15, 2016
Having a price of $13.34, Trinity Biotech plc (ADR) (NASDAQ:TRIB) traded 1.44% higher on the day. With the last stock price up 14.54% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. Trinity Biotech plc (ADR) has registered a 50-day moving average of $12.83 and two hundred day average of $11.65. Volume of trade was was up over the average, with 51,988 shares of TRIB changing hands over the typical 51,809 shares.
Zacks Investment Research has upgraded Trinity Biotech plc (ADR)(NASDAQ:TRIB) to Hold in a statement released Friday September 16 2016.
Recent Performance Chart:
Trinity Biotech plc (ADR) has a one-year low of $9.20 and a one-year high of $14.23 with a price-earnings ratio of 57 and has a market capitalization of $0.0.
Brief Synopsis About Trinity Biotech plc (ADR) (NASDAQ:TRIB)
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, and physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech’s blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.